**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 89900

**Manuscript Type:** EDITORIAL

***Ex vivo* liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment**

Tchilikidi KY. pCCA: ELRAT and systemic therapy

Konstantin Y Tchilikidi

**Konstantin Y Tchilikidi,** Department of Surgery with Postgraduate Education, Altai State Medical University, Barnaul 656031, Russia

**Author contributions:** Tchilikidi KY is the sole author of this manuscript.

**Corresponding author: Konstantin Y Tchilikidi, MD, Assistant Professor,** Department of Surgery with Postgraduate Education, Altai State Medical University, Krasnoarmeysky avenue 131-10, Barnaul 656031, Russia. kt80876@gmail.com

**Received:** November 16, 2023

**Revised:** December 26, 2023

**Accepted:** February 18, 2024

**Published online:**

**Abstract**

This editorial contains comments on the article “Systematic sequential therapy for *ex vivo* liver resection and autotransplantation: A case report and review of literature” in the recent issue of *World Journal of Gastrointestinal Surgery*. It points out the actuality and importance of the article and focuses primarily on the role and place of *ex vivo* liver resection and autotransplantation (ELRAT) and systemic therapy, underlying molecular mechanisms for targeted therapy in perihilar cholangiocarcinoma (pCCA) management. pCCA is a tough malignancy with a high proportion of advanced disease at the time of diagnosis. The only curative option is radical surgery. Surgical excision and reconstruction become extremely complicated and not always could be performed even in localized disease. On the other hand, ELRAT takes its place among surgical options for carefully selected pCCA patients. In advanced disease, systemic therapy becomes a viable option to prolong survival. This editorial describes current possibilities in chemotherapy and reveals underlying mechanisms and projections in targeted therapy with kinase inhibitors and immunotherapy in both palliative and adjuvant settings. Fibroblast grow factor and fibroblast grow factor receptor, human epidermal growth factor receptor 2, isocitrate dehydrogenase, and protein kinase cAMP activated catalytic subunit alpha (PRKACA) and beta (PRKACB) pathways have been actively investigated in CCA in last years. Several agents were introduced and approved by the Food and Drug Administration. They all demonstrated meaningful activity in CCA patients with no global change in outcomes. That is why every successfully treated patient counts, especially those with advanced disease. In conclusion, pCCA is still hard to treat due to late diagnosis and extremely complicated surgical options. ELRAT also brings some hope, but it could be performed in very carefully selected patients. Advanced disease requires systemic anticancer treatment, which is supposed to be individualized according to the genetic and molecular features of cancer cells. Targeted therapy in combination with chemo-immunotherapy could be effective in susceptible patients.

**Key Words:** Perihilar cholangiocarcinoma; Klatskin’ tumor; *Ex vivo* liver resection and autotransplantation; Chemotherapy; Immunotherapy; Targeted therapy

Tchilikidi KY. *Ex vivo* liver resection and auto-transplantation and special systemic therapy in perihilar cholangiocarcinoma treatment. *World J Gastrointest Surg* 2024; In press

**Core Tip:** Perihilar cholangiocarcinoma is still hard to treat due to late diagnosis and extremely complicated surgical options. *Ex vivo* liver resection and autotransplantation brings some hope, but it could be performed only in carefully selected patients. Advanced disease requires systemic anticancer treatment, which is supposed to be individualized according to the genetic and molecular features of cancer cells. Targeted therapy in combination with chemo-immunotherapy could be effective in susceptible patients.

**INTRODUCTION**

Cholangiocarcinoma (CCA) is the main malignancy in the biliary tract. It is classified into three subtypes according to localization. Intrahepatic CCA is the second primary liver cancer after hepatocellular carcinoma (HCC). Perihilar CCA (pCCA) or Klatskin’ tumor originates from left, right, and common hepatic ducts distal to second order biliary branches and proximal to the cystic duct confluence. Distal CCA arises from the common bile duct proximal to the Vater’s ampula. In fact, CCA is a heterogeneous group of malignancies with different genetic and molecular features[1-4]. Those genetic and molecular properties make this malignancy chemo-radio-resistant, shrinking the number of available therapeutic options.

The only curative option is radical surgery. However, the location of pCCA leads to late diagnosis of the disease frequently in advanced stage[1]. In addition, surgical excision and reconstruction become extremely complicated and not always could be performed even in localized disease.

Results of allogeneic liver transplantation (LT) in CCA did not bring this procedure to routine use like in HCC. As stated by Sapisochín *et al*[5], as well as other authors, pCCA could be an accepted indication for orthotopic LT in some centers under a strict selection process and after neoadjuvant chemoradiation. Intrahepatic CCA is a formal contraindication for LT in most centers worldwide due to the poor reported results, despite that neoadjuvant chemoradiation makes them better[5-7].

On the other hand, *ex vivo* liver resection auto-transplantation (ELRAT), since first introduced by Pichlmayr *et al*[8] in 1988, has taken its place among surgical options for non-malignant lesions and malignancies including carefully selected pCCA patients[8,9].

Systemic anticancer therapy in pCCA has common limitations as in other CCA locations. Just a few chemotherapy regimens showed certain efficacy. Due to recent advances in genetic and molecular mapping, targeted agents have started to become treatment options for selected CCA patients. They open new possibilities in advanced stage CCA. Despite everything, CCA is still a highly lethal disease that requires complicated surgical excision and is resistant to systemic therapy. That is why every successful treatment should be taken into account. One of them is the case report by Hu *et al*[10] “Systematic sequential therapy for *ex vivo* liver resection and autotransplantation: A case report and review of literature” published in the recent issue of *World Journal of Gastrointestinal Surgery*[10].

**ROLE OF *EX VIVO* LIVER RESECTION and AUTO-TRANSPLANTATION IN PERIHILAR CHOLANGIOCARCINOMA TREATMENT**

Hardy *et al*[11,12] in 1963 first reported extracorporeal procedures with organs followed by kidney re-implantation after high ureteral injury. Newly introduced in the 1980s, reduced-size, split and auxiliary LT were techniques that precluded *ex situ* liver resections[13-15]. Publications about ELRAT started with Pichlmayr *et al*[8] in 1988[8]. ELRAT allows avoiding scarce donor organs and lifelong immunosuppression. Development of this surgical procedure led to different technical subtypes. Now many authors recognize *in vivo* total hepatectomy followed by ELRAT and *in vivo* partial hepatectomy followed by ELRAT[9,16]. Despite that ELRAT started to be used in patients with malignancies, patients with benign liver diseases far overweighed them now, mainly due to hepatic alveolar echinococcosis[16-18], where some authors reported low perioperative mortality and good survival[17-20].

Results in cancer patients are still controversial with higher morbidity and mortality that do not make ELRAT become a procedure widely used in these settings[2]. According to Zawistowski *et al*[20], among 244 patients involved in 53 studies, the 30-d mortality did not differ among patients with the nonmalignant and malignant diseases (11.3% *vs* 6.3%, *P* = 0.181). The 90-d mortality was higher for malignant tumors (21.6% *vs* 8.2%, *P* = 0.004), as well as in-hospital mortality (18.3% *vs* 2.7%, *P* < 0.001). The postoperative 1-year survival was worse in the malignant group (65.0% *vs* 89.7%, *P* < 0.001). Major postoperative complications took place less commonly in the nonmalignant group (21.0% *vs* 50.0%, *P* < 0.001). Post-hepatectomy liver failure occurred more frequently among patients with malignant tumors (23.0% *vs* 8.9%, *P* = 0.006; Table 1)[20].

Nevertheless, several publications on ELRAT in malignancies including pCCA appeared in last years. That allows Kato *et al*[21] in 2020 and Weiner *et al*[22] in 2022 as well as other authors to make conclusion about this method as an alternative treatment in selective cancer patients[21,22]. Some researchers performed ELRAT for CCA with no additional anticancer therapy. Others combined them[16,23]. pCCA patients are not a preferable population for ELRAT. Despite good early results of the treatment in the article reported by Hu *et al*[16], it would be necessary to continue surveillance.

**ROLE OF SYSTEMIC CHEMOTHERAPY IN CHOLANGIOCARCINOMA MANAGEMENT**

Due to the lack of specific clinical presentations in early stages, most of biliary tract carcinomas are diagnosed as advanced disease[1,24], where patients have lost their chance for routine curative treatment. Thus, systemic anticancer therapy becomes the procedure of choice in neo-adjuvant and palliative settings. With curative resections, both adjuvant and neo-adjuvant chemotherapy prolonged overall survival and disease-free survival[25,26]. However, both studies did not find survival advantage of neo-aduvant chemotherapy *vs* adjuvant chemotherapy in sensitivity analysis. Since first reported in 2010, results of the ABC-02 trial (NCT00262769) made the gemcitabine and cisplatin regimen most popular. This doublet chemotherapy confirmed its superiority over other cytostatics. Its efficacy has allowed gemcitabine/cisplatin to become first line chemotherapy in CCA[27]. Nevertheless, this regimen could increase resectability only in few patients. In addition, most of patients required dose adaptions[28]. That forced researchers to seek other systemic agents including targeted therapy to increase survival and as a bridge to curative surgery in advanced disease.

**TARGETED THERAPY AS a TREATMENT OPTION IN CHOLANGIOCARCINOMA PATIENTS**

Rapid development of cancer genetic mapping and molecular mechanism discovery in the last decade has changed targeted therapy from experimental anticancer treatment to widely accepted. The fibroblast grow factor (FGF) and FGF receptor (FGFR) pathway is considered to be one of the most important pathways in CCA. Munugala *et al*[29] further discovered that the isocitrate dehydrogenase mutations took a significant percentage in different subsets of CCA[29,30]. Drugs include infigratinib, erdafitinib, TAS-120 (an irreversible pan-FGFR inhibitor), pemigatinib (a potent, selective oral inhibitor of FGFR isoforms 1, 2, and 3). Pemigatinib becomes the first Food and Drug Administration (FDA) approved anti-FGFR2 agent. They all demonstrated meaningful activity in CCA patients with no global change in outcomes[29,30]. Some other authors considered that extrahepatic CCA including pCCA is more related to human epidermal growth factor receptor 2 (HER2) and the protein kinase cAMP activated catalytic subunit alpha (PRKACA) and beta (PRKACB) pathways[31,32]. The antibody-drug conjugate trastuzumab emtansine experimentally used by some researchers in CCA settings showed higher activity in CCA cell lines with higher HER2 expression[33,34], though HER2 agents act indirectly on the FGF/FGFR pathway too[29,30].

Immunotherapy becomes a game changer in some malignancies such as melanoma, but unfortunately not in CCA. Results of programmed death protein ligand 1 (PD-L1) inhibitors pembrolizumab and nivolumab were mixed[29,35-37]. Programmed death protein 1 (PD-1)/PD-L1 inhibitors can be used in high microsatellite instable (MSI-H) tumors. MSI-H as a result of DNA mismatch repair defects (dMMR) could appear in different malignancies. MSI-H is rare in intrahepatic CCA, but more frequent in extrahepatic CCA[38]. The phase III TOPAZ-1 trial presented promising results for the PD-L1 inhibitor durvalumab in combination with gemcitabine/cisplatin, mostly confirmed by Rimini *et al*[39] and Macias *et al*[40]. Macias *et al*[40] in their recent editorial article called the above regimen “new first-line standard of care for patients with advanced biliary tract cancer after more than 10 years of chemotherapy alone”[40,41]. The FDA recommended pembrolizumab as a second line therapy for MSI-H/dMMR cancers[42,43]. Results of the phase III KEYNOTE-966 trial showed survival benefit by adding pembrolizumab to gemcitabine/cisplatin in advanced CCA[44].

Lenvatinib, as a multi-kinase inhibitor of VEGF receptors 1–3, FGF receptors 1–4, platelet derived growth factor receptor α, KIT, and RET, selectively inhibits tyrosine kinase receptors involved in tumor growth and angiogenesis[45]. Tislelizumab is a PD-1 monoclonal IgG4 antibody of high affinity that is mainly used in hematological malignancies and advanced solid cancers, which was conditionally approved in China[45]. Ding *et al*[45] reported successful neoadjuvant therapy with gemcitabine/cisplatin/lenvatinib/tislelizumab in patients with advanced intraheptic CCA followed by surgical resection with no recurrence at the 10-month follow-up[45].

Infigratinib is a reversible ATP-competitive FGFR 1–3 inhibitor. It is actively investigating now. Yu *et al*[46] concluded that tumor resistance to reversible FGFR inhibitors including infigratinib could be a barrier for the clinical benefits of infigratinib in CCA. They also proposed perspectives with its future administration in combination with immunotherapy[46].

Anticancer therapy in the article of Hu *et al*[10] included conditionally approved agents. So again, further surveillance is necessary.

**CONCLUSION**

pCCA is still hard to treat due to late diagnosis and extremely complicated surgical options. ELRAT also brings some hope, but it could be performed only in carefully selected patients. Advanced disease requires systemic anticancer treatment, which is supposed to be individualized according to the genetic and molecular features of cancer cells. Targeted therapy in combination with chemo-immunotherapy could be effective in susceptible patients.

**REFERENCES**

1 **Banales JM**, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 557-588 [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z]

2 **Brindley PJ**, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. *Nat Rev Dis Primers* 2021; **7**: 65 [PMID: 34504109 DOI: 10.1038/s41572-021-00300-2]

3 **Moris D**, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. *CA Cancer J Clin* 2023; **73**: 198-222 [PMID: 36260350 DOI: 10.3322/caac.21759]

4 **DeOliveira ML**, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. *Ann Surg* 2007; **245**: 755-762 [PMID: 17457168 DOI: 10.1097/01.sla.0000251366.62632.d3]

5 **Sapisochín G**, Fernández de Sevilla E, Echeverri J, Charco R. Liver transplantation for cholangiocarcinoma: Current status and new insights. *World J Hepatol* 2015; **7**: 2396-2403 [PMID: 26464755 DOI: 10.4254/wjh.v7.i22.2396]

6 **Safarpour AR**, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? *World J Gastrointest Pathophysiol* 2021; **12**: 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84]

7 **Giovinazzo F**, Pascale MM, Cardella F, Picarelli M, Molica S, Zotta F, Martullo A, Clarke G, Frongillo F, Grieco A, Agnes S. Current Perspectives in Liver Transplantation for Perihilar Cholangiocarcinoma. *Curr Oncol* 2023; **30**: 2942-2953 [PMID: 36975438 DOI: 10.3390/curroncol30030225]

8 **Pichlmayr R**, Bretschneider HJ, Kirchner E, Ringe B, Lamesch P, Gubernatis G, Hauss J, Niehaus KJ, Kaukemüller J. [*Ex situ* operation on the liver. A new possibility in liver surgery]. *Langenbecks Arch Chir* 1988; **373**: 122-126 [PMID: 3287072 DOI: 10.1007/BF01262775]

9 **Yang X,** Lu L, Zhu WW, Tao YF, Shen CH, Chen JH, Wang ZX, Qin LX. *Ex vivo* liver resection and auto-transplantation as an alternative to treat liver malignancies: Progress and challenges. *Hepatobiliary Pancreat Dis Int* 2023; In Press [DOI: 10.1016/j.hbpd.2023.10.007]

10 **Hu CL**, Han X, Gao ZZ, Zhou B, Tang JL, Pei XR, Lu JN, Xu Q, Shen XP, Yan S, Ding Y. Systematic sequential therapy for *ex vivo* liver resection and autotransplantation: A case report and review of literature. *World J Gastrointest Surg* 2023; **15**: 2663-2673 [PMID: 38111758 DOI: 10.4240/wjgs.v15.i11.2663]

11 **HARDY JD**. High ureteral injuries. Management by autotransplantation of the kidney. *JAMA* 1963; **184**: 97-101 [PMID: 13960761 DOI: 10.1001/jama.1963.03700150051008]

12 **HARDY JD**, ERASLAN S. AUTOTRANSPLANTATION OF THE KIDNEY FOR HIGH URETERAL INJURY. *J Urol* 1963; **90**: 563-574 [PMID: 14079696 DOI: 10.1016/S0022-5347(17)64454-9]

13 **Broelsch CE**, Emond JC, Thistlethwaite JR, Whitington PF, Zucker AR, Baker AL, Aran PF, Rouch DA, Lichtor JL. Liver transplantation, including the concept of reduced-size liver transplants in children. *Ann Surg* 1988; **208**: 410-420 [PMID: 3052326 DOI: 10.1097/00000658-198810000-00003]

14 **Emond JC**, Whitington PF, Thistlethwaite JR, Alonso EM, Broelsch CE. Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease. *Hepatology* 1989; **10**: 867-872 [PMID: 2807168 DOI: 10.1002/hep.1840100520]

15 **Pichlmayr R**, Ringe B, Gubernatis G, Hauss J, Bunzendahl H. [Transplantation of a donor liver to 2 recipients (splitting transplantation)--a new method in the further development of segmental liver transplantation]. *Langenbecks Arch Chir* 1988; **373**: 127-130 [PMID: 3287073 DOI: 10.1007/BF01262776]

16 **Xu S**, Hu C, Jiang Z, Li G, Zhou B, Gao Z, Yan S. In vivo total or partial hepatectomy followed by *ex vivo* liver resection and autotransplantation for malignant tumors: a single center experience. *Front Oncol* 2023; **13**: 1214451 [PMID: 37427118 DOI: 10.3389/fonc.2023.1214451]

17 **Aji T**, Dong JH, Shao YM, Zhao JM, Li T, Tuxun T, Shalayiadang P, Ran B, Jiang TM, Zhang RQ, He YB, Huang JF, Wen H. Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis. *J Hepatol* 2018; **69**: 1037-1046 [PMID: 30031886 DOI: 10.1016/j.jhep.2018.07.006]

18 **Qiu Y**, Huang B, Yang X, Wang T, Shen S, Yang Y, Wang W. Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis. *Clin Infect Dis* 2022; **75**: 1289-1296 [PMID: 35271705 DOI: 10.1093/cid/ciac195]

19 **Beldi G**, Vuitton D, Lachenmayer A, Heyd B, Dufour JF, Richou C, Candinas D, Bresson-Hadni S. Is *ex vivo* liver resection and autotransplantation a valid alternative treatment for end-stage hepatic alveolar echinococcosis in Europe? *J Hepatol* 2019; **70**: 1030-1031 [PMID: 30718093 DOI: 10.1016/j.jhep.2018.12.011]

20 **Zawistowski M**, Nowaczyk J, Jakubczyk M, Domagała P. Outcomes of ex vivo liver resection and autotransplantation: A systematic review and meta-analysis. *Surgery* 2020; **168**: 631-642 [PMID: 32727659 DOI: 10.1016/j.surg.2020.05.036]

21 **Kato T**, Hwang R, Liou P, Weiner J, Griesemer A, Samstein B, Halazun K, Mathur A, Schwartz G, Cherqui D, Emond J. Ex Vivo Resection and Autotransplantation for Conventionally Unresectable Tumors - An 11-year Single Center Experience. *Ann Surg* 2020; **272**: 766-772 [PMID: 32833756 DOI: 10.1097/SLA.0000000000004270]

22 **Weiner J**, Hemming A, Levi D, Beduschi T, Matsumoto R, Mathur A, Liou P, Griesemer A, Samstein B, Cherqui D, Emond J, Kato T. Ex Vivo Liver Resection and Autotransplantation: Should It be Used More Frequently? *Ann Surg* 2022; **276**: 854-859 [PMID: 35920562 DOI: 10.1097/SLA.0000000000005640]

23 **George A**, Rammohan A, Reddy SM, Rela M. *Ex situ* liver resection and autotransplantation for advanced cholangiocarcinoma. *BMJ Case Rep* 2019; **12** [PMID: 31431431 DOI: 10.1136/bcr-2019-230808]

24 **Valle JW**, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. *Lancet* 2021; **397**: 428-444 [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7]

25 **Hassan H**, Chakrabarti S, Zemla T, Yin J, Wookey V, Prasai K, Abdellatief A, Katta R, Tran N, Jin Z, Cleary S, Roberts L, Mahipal A. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. *Eur J Surg Oncol* 2023; **49**: 106994 [PMID: 37524649 DOI: 10.1016/j.ejso.2023.106994]

26 **Parente A**, Kamarajah SK, Baia M, Tirotta F, Manzia TM, Hilal MA, Pawlik TM, White SA, Dahdaleh FS. Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. *J Gastrointest Surg* 2023; **27**: 741-749 [PMID: 36749556 DOI: 10.1007/s11605-023-05606-y]

27 **Valle J**, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine *vs* gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

28 **Möhring C**, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. *Front Oncol* 2021; **11**: 717397 [PMID: 34858809 DOI: 10.3389/fonc.2021.717397]

29 **Munugala N**, Maithel SK, Shroff RT. Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. *Hepatobiliary Surg Nutr* 2022; **11**: 253-266 [PMID: 35464290 DOI: 10.21037/hbsn-20-475]

30 **Goyal L**, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. *Cancer Treat Rev* 2021; **95**: 102170 [PMID: 33735689 DOI: 10.1016/j.ctrv.2021.102170]

31 **Nakamura H**, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T. Genomic spectra of biliary tract cancer. *Nat Genet* 2015; **47**: 1003-1010 [PMID: 26258846 DOI: 10.1038/ng.3375]

32 **Jain A**, Javle M. Molecular profiling of biliary tract cancer: a target rich disease. *J Gastrointest Oncol* 2016; **7**: 797-803 [PMID: 27747093 DOI: 10.21037/jgo.2016.09.01]

33 **Yamashita-Kashima Y**, Yoshimura Y, Fujimura T, Shu S, Yanagisawa M, Yorozu K, Furugaki K, Higuchi R, Shoda J, Harada N. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate. *Cancer Chemother Pharmacol* 2019; **83**: 659-671 [PMID: 30659304 DOI: 10.1007/s00280-019-03768-8]

34 **Kuwatani M**, Sakamoto N. Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. *Cancers (Basel)* 2023; **15** [PMID: 37509347 DOI: 10.3390/cancers15143686]

35 **Kang J**, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW, Song TJ, Kim KH, Hwang S, Hwang DW, Kim SC, Park JH, Hong SM, Kim KP, Ryoo BY, Yoo C. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. *Cancer Res Treat* 2020; **52**: 594-603 [PMID: 32019287 DOI: 10.4143/crt.2019.493]

36 **Kim RD**, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, Schell MJ, Zhou JM, Mahipal A, Kim BH, Kim DW. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. *JAMA Oncol* 2020; **6**: 888-894 [PMID: 32352498 DOI: 10.1001/jamaoncol.2020.0930]

37 **Wang M**, Chen Z, Guo P, Wang Y, Chen G. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential. *J Cell Mol Med* 2021; **25**: 618-628 [PMID: 33277810 DOI: 10.1111/jcmm.16151]

38 **Winkelmann R**, Schneider M, Hartmann S, Schnitzbauer AA, Zeuzem S, Peveling-Oberhag J, Hansmann ML, Walter D. Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. *Int J Mol Sci* 2018; **19** [PMID: 29747443 DOI: 10.3390/ijms19051421]

39 **Rimini M**, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E, Pirrone C, Rapposelli IG, Diana A, Martinelli E, Garajová I, Simionato F, Schirripa M, Formica V, Vivaldi C, Caliman E, Rizzato MD, Zanuso V, Nichetti F, Angotti L, Landriscina M, Scartozzi M, Ramundo M, Pastorino A, Daniele B, Cornara N, Persano M, Gusmaroli E, Cerantola R, Salani F, Ratti F, Aldrighetti L, Cascinu S, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. *Liver Int* 2023; **43**: 1803-1812 [PMID: 37452505 DOI: 10.1111/liv.15641]

40 **Macias RIR**, Rimassa L, Lamarca A. The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment. *Hepatobiliary Surg Nutr* 2023; **12**: 457-461 [PMID: 37351132 DOI: 10.21037/hbsn-23-215]

41 **Du J**, Lv X, Zhang Z, Huang Z, Zhang E. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. *Front Immunol* 2023; **14**: 1142690 [PMID: 36936931 DOI: 10.3389/fimmu.2023.1142690]

42 **Marcus L**, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, Pazdur R, Lemery SJ. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. *Clin Cancer Res* 2021; **27**: 4685-4689 [PMID: 34083238 DOI: 10.1158/1078-0432.CCR-21-0327]

43 **Simile MM**, Bagella P, Vidili G, Spanu A, Manetti R, Seddaiu MA, Babudieri S, Madeddu G, Serra PA, Altana M, Paliogiannis P. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials. *Medicina (Kaunas)* 2019; **55** [PMID: 30743998 DOI: 10.3390/medicina55020042]

44 **Kelley RK**, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2023; **401**: 1853-1865 [PMID: 37075781 DOI: 10.1016/S0140-6736(23)00727-4]

45 **Ding Y**, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. *Front Oncol* 2021; **11**: 691380 [PMID: 34527576 DOI: 10.3389/fonc.2021.691380]

46 **Yu J**, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. *Onco Targets Ther* 2021; **14**: 5145-5160 [PMID: 34720591 DOI: 10.2147/OTT.S272208]

**Footnotes**

**Conflict-of-interest statement:** The author reports no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 16, 2023

**First decision:** December 17, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Russia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yu HP, China **S-Editor: L-Editor:** Wang TQ **P-Editor:**

**Table 1 Results of *ex vivo* liver resection and auto-transplantation in malignant and non-malignant settings (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Issue** | **Non-malignant diseases** | **Malignant tumors** | ***P* value** |
| 30-d mortality | 6.3 | 11.3 | = 0.181 |
| 90-d mortality | 8.2 | 12.5 | = 0.004 |
| In-hospital mortality | 2.7 | 18.3 | < 0.001 |
| 1-year survival | 89.7 | 65.0 | < 0.001 |
| Major postoperative complications | 21.0 | 50.0 | < 0.001 |
| Post-hepatectomy liver failure | 8.9 | 23.0 | = 0.006 |